Table 1: Human melanoma correlative study.

IHC staining towards CD3 and PRMT7 was established on nine human melanoma patient samples (FFPE tumor sections) treated with anti-PD-1 and carbotaxol. The level of CD3 and PRMT7 protein expression in the melanomas were scored and grouped according to whether they received clinical benefit from immunotherapy or not. 5 good responding tumors (GR: Good Responders) and 4 non-responding tumors (PR, Poor responders). The immune score was obtained from semi-quantitative prevalence of CD3⁺ cells noted as absent (0), focal (1), moderate (2) or severe (3). For the PRMT7 staining, the score was noted as POS for a positive PRMT7 nuclear staining or as NEG for a negative PRMT7 nuclear staining (absence of PRMT7 expression: low or undetectable).